We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Read MoreHide Full Article
Key Takeaways
Vertex Pharmaceuticals awaits a Nov. 30 FDA decision on povetacicept filing for IgA nephropathy.
Amylyx expects third-quarter 2026 phase III LUCIDITY results for avexitide in post-bariatric hypoglycemia.
Praxis expects an FDA decision on relutrigine for DEEs by Dec. 27, followed by EMERALD study data in Q4.
The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy and commercial potential.
Pipeline milestones are therefore key stock catalysts. Clinical data can validate or undermine a candidate, while regulatory decisions can bring it closer to commercialization. Late-stage data and regulatory milestones generally have a significant impact on stock prices as they offer more clarity on a drug's approval prospects.
Against this backdrop, Vertex Pharmaceuticals (VRTX - Free Report) , Amylyx Pharmaceuticals (AMLX - Free Report) , Praxis Precision Medicines (PRAX - Free Report) and BridgeBio Pharma (BBIO - Free Report) stand out for having notable pipeline/regulatory developments during the second half of 2026. With multiple clinical and regulatory milestones spanning pain, metabolic disorders, neurological diseases and rare genetic conditions, these companies offer several potentially meaningful catalysts, making the four biotech stocks particularly compelling investment opportunities.
Vertex Pharmaceuticals
The key near-term catalyst for Vertex is the FDA’s pending decision on a biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN), scheduled for Nov. 30, 2026. Acquired from Alpine Immune Sciences, povetacicept is being developed as a potential best-in-class therapy for multiple B-cell-mediated diseases and could help Vertex expand beyond its established cystic fibrosis franchise.
Year to date, VRTX shares have gained 15.6% compared with the industry’s 5.2% growth.
Image Source: Zacks Investment Research
The upcoming FDA decision could be particularly important given povetacicept’s potential role in establishing Vertex’s presence in nephrology. If approved, povetacicept would become Vertex’s first commercialized therapy in nephrology, creating a potential new source of product revenues and growth. The company is also advancing povetacicept in primary membranous nephropathy, another B-cell-mediated disease, and has completed the phase IIB portion of the mid- to late-stage program. Conversely, a regulatory setback could delay the candidate’s commercial prospects and weaken expectations for its contribution to Vertex’s longer-term growth. VRTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Amylyx Pharmaceuticals
Amylyx's lead candidate, avexitide, a GLP-1 receptor antagonist, is being developed for post-bariatric hypoglycemia, a condition for which there are currently no FDA-approved therapies. The key near-term catalyst is top-line results from the phase III LUCIDITY study, which Amylyx expects to report in the third quarter of 2026. The study has completed enrollment, with its primary endpoint being the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16.
Year to date, AMLX shares have soared 87.6% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
The upcoming readout could be particularly important given avexitide’s central role in Amylyx’s pipeline. Earlier clinical studies have demonstrated consistent, dose-dependent effects, providing a supportive backdrop ahead of the pivotal readout. If the phase III study is successful and avexitide is subsequently approved, Amylyx aims to launch the drug commercially in 2027. This would give the company its first marketed drug and a potential recurring source of product revenues, making the LUCIDITY outcome a significant inflection point. Conversely, an unfavorable result could materially weaken avexitide’s regulatory and commercial prospects. Amylyx is also exploring avexitide in congenital hyperinsulinism. AMLX currently carries a Zacks Rank #3.
Praxis Precision Medicines
A potential FDA approval for relutrigine in genetically defined developmental epileptic encephalopathies (DEEs) is Praxis' most prominent second-half catalyst. The new drug application (NDA) is supported by positive results from the registrational cohort of the phase II/III EMBOLD study, which met its primary efficacy objective, demonstrating a 53% placebo-adjusted reduction in monthly motor seizures over 16 weeks in patients with SCN2A- and SCN8A-related DEEs. Although the drug initially received priority review with a Sept. 27, 2026, decision date, the FDA extended the review period by three months, establishing a new Dec. 27, 2026, target action date. The mid-cycle meeting was completed without major safety or efficacy concerns identified to date, and no advisory committee meeting is planned.
Year to date, PRAX shares have rallied 24.6% compared with the industry’s 5.3% growth.
Image Source: Zacks Investment Research
The catalyst is not limited to the regulatory decision. The EMERALD study, evaluating relutrigine in patients with broader DEEs, has completed recruitment and is expected to report top-line results in the fourth quarter of 2026. If positive, the study could support a supplemental NDA in 2027, potentially expanding the commercial opportunity beyond the genetically defined SCN2A- and SCN8A-DEE populations covered by the initial application. PRAX currently carries a Zacks Rank #3.
BridgeBio Pharma
FDA action on BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) represents BridgeBio's major second-half catalyst. BBP-418 is an investigational oral glycosylation substrate therapy with a unique mechanism of action that could improve muscle, ambulatory and cardiopulmonary function. Its differentiated proposition is particularly notable because, if approved, BBP-418 could become the first and only approved therapy for LGMD2I/R9 and potentially the first approved therapy for any form of limb-girdle muscular dystrophy.
Year to date, BridgeBioshares have gained 10.7% compared with the industry’s 6.8% growth.
Image Source: Zacks Investment Research
The candidate has already cleared a major clinical hurdle. In the phase III FORTIFY study, BBP-418 met all primary and secondary endpoints at the prespecified 12-month interim analysis, with treated participants improving while placebo recipients declined across key measures. The FDA subsequently accepted BridgeBio's NDA for Priority Review and assigned a decision date of Nov. 27, 2026. The agency is not currently planning an advisory committee meeting, further focusing attention on the regulatory decision itself. BridgeBio also intends to initiate studies in younger LGMD2I/R9 patients and in additional LGMD subtypes, providing potential avenues for label expansion if the initial regulatory outcome is favorable. BBIO currently carries a Zacks Rank #3.
View the Zacks #1 Rank List
Image: Bigstock
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Key Takeaways
The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy and commercial potential.
Pipeline milestones are therefore key stock catalysts. Clinical data can validate or undermine a candidate, while regulatory decisions can bring it closer to commercialization. Late-stage data and regulatory milestones generally have a significant impact on stock prices as they offer more clarity on a drug's approval prospects.
Against this backdrop, Vertex Pharmaceuticals (VRTX - Free Report) , Amylyx Pharmaceuticals (AMLX - Free Report) , Praxis Precision Medicines (PRAX - Free Report) and BridgeBio Pharma (BBIO - Free Report) stand out for having notable pipeline/regulatory developments during the second half of 2026. With multiple clinical and regulatory milestones spanning pain, metabolic disorders, neurological diseases and rare genetic conditions, these companies offer several potentially meaningful catalysts, making the four biotech stocks particularly compelling investment opportunities.
Vertex Pharmaceuticals
The key near-term catalyst for Vertex is the FDA’s pending decision on a biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN), scheduled for Nov. 30, 2026. Acquired from Alpine Immune Sciences, povetacicept is being developed as a potential best-in-class therapy for multiple B-cell-mediated diseases and could help Vertex expand beyond its established cystic fibrosis franchise.
Year to date, VRTX shares have gained 15.6% compared with the industry’s 5.2% growth.
Image Source: Zacks Investment Research
The upcoming FDA decision could be particularly important given povetacicept’s potential role in establishing Vertex’s presence in nephrology. If approved, povetacicept would become Vertex’s first commercialized therapy in nephrology, creating a potential new source of product revenues and growth. The company is also advancing povetacicept in primary membranous nephropathy, another B-cell-mediated disease, and has completed the phase IIB portion of the mid- to late-stage program. Conversely, a regulatory setback could delay the candidate’s commercial prospects and weaken expectations for its contribution to Vertex’s longer-term growth. VRTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Amylyx Pharmaceuticals
Amylyx's lead candidate, avexitide, a GLP-1 receptor antagonist, is being developed for post-bariatric hypoglycemia, a condition for which there are currently no FDA-approved therapies. The key near-term catalyst is top-line results from the phase III LUCIDITY study, which Amylyx expects to report in the third quarter of 2026. The study has completed enrollment, with its primary endpoint being the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16.
Year to date, AMLX shares have soared 87.6% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
The upcoming readout could be particularly important given avexitide’s central role in Amylyx’s pipeline. Earlier clinical studies have demonstrated consistent, dose-dependent effects, providing a supportive backdrop ahead of the pivotal readout. If the phase III study is successful and avexitide is subsequently approved, Amylyx aims to launch the drug commercially in 2027. This would give the company its first marketed drug and a potential recurring source of product revenues, making the LUCIDITY outcome a significant inflection point. Conversely, an unfavorable result could materially weaken avexitide’s regulatory and commercial prospects. Amylyx is also exploring avexitide in congenital hyperinsulinism. AMLX currently carries a Zacks Rank #3.
Praxis Precision Medicines
A potential FDA approval for relutrigine in genetically defined developmental epileptic encephalopathies (DEEs) is Praxis' most prominent second-half catalyst. The new drug application (NDA) is supported by positive results from the registrational cohort of the phase II/III EMBOLD study, which met its primary efficacy objective, demonstrating a 53% placebo-adjusted reduction in monthly motor seizures over 16 weeks in patients with SCN2A- and SCN8A-related DEEs. Although the drug initially received priority review with a Sept. 27, 2026, decision date, the FDA extended the review period by three months, establishing a new Dec. 27, 2026, target action date. The mid-cycle meeting was completed without major safety or efficacy concerns identified to date, and no advisory committee meeting is planned.
Year to date, PRAX shares have rallied 24.6% compared with the industry’s 5.3% growth.
Image Source: Zacks Investment Research
The catalyst is not limited to the regulatory decision. The EMERALD study, evaluating relutrigine in patients with broader DEEs, has completed recruitment and is expected to report top-line results in the fourth quarter of 2026. If positive, the study could support a supplemental NDA in 2027, potentially expanding the commercial opportunity beyond the genetically defined SCN2A- and SCN8A-DEE populations covered by the initial application. PRAX currently carries a Zacks Rank #3.
BridgeBio Pharma
FDA action on BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) represents BridgeBio's major second-half catalyst. BBP-418 is an investigational oral glycosylation substrate therapy with a unique mechanism of action that could improve muscle, ambulatory and cardiopulmonary function. Its differentiated proposition is particularly notable because, if approved, BBP-418 could become the first and only approved therapy for LGMD2I/R9 and potentially the first approved therapy for any form of limb-girdle muscular dystrophy.
Year to date, BridgeBioshares have gained 10.7% compared with the industry’s 6.8% growth.
Image Source: Zacks Investment Research
The candidate has already cleared a major clinical hurdle. In the phase III FORTIFY study, BBP-418 met all primary and secondary endpoints at the prespecified 12-month interim analysis, with treated participants improving while placebo recipients declined across key measures. The FDA subsequently accepted BridgeBio's NDA for Priority Review and assigned a decision date of Nov. 27, 2026. The agency is not currently planning an advisory committee meeting, further focusing attention on the regulatory decision itself. BridgeBio also intends to initiate studies in younger LGMD2I/R9 patients and in additional LGMD subtypes, providing potential avenues for label expansion if the initial regulatory outcome is favorable. BBIO currently carries a Zacks Rank #3.